Eylea HD 8 MG/0.07 ML vial 0.07ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRRH6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,176
Award facts
- Contract value 100% obligated
- $16,176.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,176 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EYLEA HD 8 mg/0.07 ml vials. The award, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to support recurring medical supply needs of military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the Department of Defense pharmaceutical supply chain, with its product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's established performance on numerous delivery orders ranging from under $100 to over $115,000 positions it as a capable regional prime vendor contractor under the PPV-G GEN V program. The IDC, awarded on November 13, 2025, with a $499,999,999 ceiling and completion date of December 31, 2036, comprises a 30-month base period with three 30-month option periods, enabling DLA to leverage DMS Pharmaceutical Group's capabilities to fulfill diverse and specialized pharmaceutical requirements across the military medical system.
Quick answers
Who was awarded contract SPE2DR26FRRH6?
SPE2DR26FRRH6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FRRH6 worth?
The government has obligated $16,176 on SPE2DR26FRRH6.
Is contract SPE2DR26FRRH6 an order under another contract?
Yes. SPE2DR26FRRH6 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRH6 competed?
The extent of competition for SPE2DR26FRRH6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award